Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons

M. F. Powell; J. L. Cleland; D. J. Eastman; A. Lim; M. J. Newman; J. H. Nunberg; R. P. Weissburg; J. C. Vennari; T. Wrin; P. W. Berman

Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons

M. F. Powell, J. L. Cleland, D. J. Eastman, A. Lim, M. J. Newman, J. H. Nunberg, R. P. Weissburg, J. C. Vennari, T. Wrin, P. W. Berman

Montana Biotechnology Center

Genentech Incorporated

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

The effect of adjuvant and immunization schedule on the immunogenicity of HIV-1 envelope glycoprotein, MN rgp120, was optimized by using baboons. The novel adjuvant QS21 elicited earlier seroconversion than alum adjuvant, and the antibody titers to MN rgp120 for animals treated with QS21 were significantly greater than the titers obtained in animals treated with alum. The use of QS21 shifted the dose-response curve, resulting in less MN rgp120 required to achieve equivalent titers to those in the alum formulations. The in vitro virus neutralizing (VN) titers from animals treated with QS21 were 3- to 10-fold higher than with alum. The data presented herein point to the superiority of QS21 as adjuvant in primates for MN rgp120.

Original language	English
Pages (from-to)	S105-S108
Journal	AIDS Research and Human Retroviruses
Volume	10
Issue number	SUPPL. 2
State	Published - 1994

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{bbdaad09aaee4e74ba03b7ffbb3af118,

title = "Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons",

abstract = "The effect of adjuvant and immunization schedule on the immunogenicity of HIV-1 envelope glycoprotein, MN rgp120, was optimized by using baboons. The novel adjuvant QS21 elicited earlier seroconversion than alum adjuvant, and the antibody titers to MN rgp120 for animals treated with QS21 were significantly greater than the titers obtained in animals treated with alum. The use of QS21 shifted the dose-response curve, resulting in less MN rgp120 required to achieve equivalent titers to those in the alum formulations. The in vitro virus neutralizing (VN) titers from animals treated with QS21 were 3- to 10-fold higher than with alum. The data presented herein point to the superiority of QS21 as adjuvant in primates for MN rgp120.",

author = "Powell, {M. F.} and Cleland, {J. L.} and Eastman, {D. J.} and A. Lim and Newman, {M. J.} and Nunberg, {J. H.} and Weissburg, {R. P.} and Vennari, {J. C.} and T. Wrin and Berman, {P. W.}",

year = "1994",

language = "English",

volume = "10",

pages = "S105--S108",

journal = "AIDS Research and Human Retroviruses",

issn = "0889-2229",

publisher = "Mary Ann Liebert Inc.",

number = "SUPPL. 2",

}

TY - JOUR

T1 - Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons

AU - Powell, M. F.

AU - Cleland, J. L.

AU - Eastman, D. J.

AU - Lim, A.

AU - Newman, M. J.

AU - Nunberg, J. H.

AU - Weissburg, R. P.

AU - Vennari, J. C.

AU - Wrin, T.

AU - Berman, P. W.

PY - 1994

Y1 - 1994

N2 - The effect of adjuvant and immunization schedule on the immunogenicity of HIV-1 envelope glycoprotein, MN rgp120, was optimized by using baboons. The novel adjuvant QS21 elicited earlier seroconversion than alum adjuvant, and the antibody titers to MN rgp120 for animals treated with QS21 were significantly greater than the titers obtained in animals treated with alum. The use of QS21 shifted the dose-response curve, resulting in less MN rgp120 required to achieve equivalent titers to those in the alum formulations. The in vitro virus neutralizing (VN) titers from animals treated with QS21 were 3- to 10-fold higher than with alum. The data presented herein point to the superiority of QS21 as adjuvant in primates for MN rgp120.

AB - The effect of adjuvant and immunization schedule on the immunogenicity of HIV-1 envelope glycoprotein, MN rgp120, was optimized by using baboons. The novel adjuvant QS21 elicited earlier seroconversion than alum adjuvant, and the antibody titers to MN rgp120 for animals treated with QS21 were significantly greater than the titers obtained in animals treated with alum. The use of QS21 shifted the dose-response curve, resulting in less MN rgp120 required to achieve equivalent titers to those in the alum formulations. The in vitro virus neutralizing (VN) titers from animals treated with QS21 were 3- to 10-fold higher than with alum. The data presented herein point to the superiority of QS21 as adjuvant in primates for MN rgp120.

UR - http://www.scopus.com/inward/record.url?scp=0028149663&partnerID=8YFLogxK

M3 - Article

C2 - 7865282

AN - SCOPUS:0028149663

SN - 0889-2229

VL - 10

SP - S105-S108

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

IS - SUPPL. 2

ER -

Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this